Onconetix Inc Ordinary Shares ONCO 深 滬
等待開盤 10-13 09:30:00 美东时间
3.65
-0.470
-11.41%
華盛通- 最 高4.1401
- 今 開4.10
- 成交量 14.67万股
- 最 低 3.58
- 昨 收 4.12
- 總市值 564.18万
- 52周最高 509.15
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.45
- 委 比 -67.33%
- 總股本 154.57万
- 歷史最高 309060.00
- 量 比 0.86
- 振 幅 13.59%
- 歷史最低 3.58
- 每 手 1
- 風險率 106.43%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Major pharmaceutical companies presenting at...
10-07 20:00
Onconetix Completes PIPE Financing Transaction
The latest announcement is out from Onconetix ( ($ONCO) ). On October 1, 2025, ...
10-03 20:48
Onco-Innovations Advances Preclinical Program with Nucro-Technics Collaboration
Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an announcement. Onco-Innova...
09-30 03:08
Onconetix Completes $12.9M Private Placement
Onconetix ( ($ONCO) ) has issued an announcement. On September 22, 2025, Oncone...
09-26 21:15
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
Onconetix, Inc. completed a $12.9 million private placement of Series D Convertible Preferred Stock and warrants, with $9.3 million paid in cash and $3.6 million used to offset debts. The Series D Preferred Stock is convertible into 4.36 million shares of common stock, and the warrants have an exercise price of $3.6896 per share. Proceeds will be used to terminate a previous business combination with Ocuvex and for working capital. Onconetix also...
09-26 12:30
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
Onconetix, Inc. and Ocuvex Therapeutics, Inc. have mutually terminated their merger agreement, deciding to pursue independent paths. Both companies remain committed to advancing their missions and delivering value to patients. Ocuvex has received its New Jersey state pharmaceutical license and is set to launch Omlonti commercially in the coming weeks. Onconetix and Ocuvex appreciate the collaborative spirit during the merger discussions.
09-26 12:15
Onconetix's Proteomedix Licenses Key Antibody Technology To Immunovia For Pancreatic Cancer Test; In Return, Immunovia Will Make Payments Totaling $700K To Proteomedix In 2025 And 2026, As Well As Pay A 3% Royalty On Net Sales Of PancreaSure And Any Other Products Incorporating The Licensed Intellectual Property From 2026 To 2032
Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology,
09-22 20:16
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM
Onconetix, Inc. subsidiary Proteomedix AG has signed a licensing agreement with Immunovia AB, a Swedish pancreatic cancer diagnostics company. The agreement allows Immunovia to use Proteomedix's master cells and intellectual property for producing antibodies related to three biomarkers in the PancreaSure test. Immunovia will pay $700,000 in 2025-2026 and a 3% royalty on net sales from 2026 to 2032. Proteomedix CEO Beat Rheiner expressed pride in ...
09-22 12:00
Onco-Innovations Partners with Dalton Pharma for Nanoparticle Manufacturing
The latest announcement is out from Onco-Innovations Ltd. ( ($TSE:ONCO) ). Onco...
09-20 06:38
Onco-Innovations to Lead Colorectal Cancer Precision Oncology Forum
Onco-Innovations Ltd. ( ($TSE:ONCO) ) has provided an update. Onco-Innovations ...
09-13 06:43
